|Articles|June 22, 2017
PAREXEL is Acquired by Pamplona Capital Management
Advertisement
PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Applied Clinical Trials at the 2026 DIA Global Annual Meeting: Conversations on Data, Outsourcing, and the Patient Voice
2
Nature Medicine Retracts Viral Lung Cancer Timing Study After Four-Month Investigation
3
ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval
4
ACT Brief: DIA Leadership Amid Uncertainty, Reimagining CRO Contracts, and Eli Lilly Expansion
5